17May 2023
Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers

Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers

This study investigates the hypothesis that weight loss with the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) liraglutide alone would lead to a more significant reduction in the proportion of fat to lean tissue mass when compared to caloric restriction (CR) alone, as well as when compared to treatment with sitagliptin, a dipeptidyl peptidase‐4 (DPP‐4) inhibitor, that also enhances GLP‐1 activity ‐ to determine the independent effects of each treatment. Based on the study results, although liraglutide and CR are valuable strategies for cardiometabolic risk reduction, CR was associated with more significant weight loss and more favourable improvements in body composition than treatment with liraglutide alone. Differences in response to these interventions enable patients to be stratified to the most optimal intervention for their personal risk factors.

  • #endo-diabetology

Like

Save

Share